13808-71-4

Basic information

• Product Name: AKOS PAO-1148
• Synonyms: AKOS PAO-1148;3-Ethyl-1H-pyrazole;3-ethyl-2H-pyrazole
• CAS NO: 13808-71-4
• Molecular Formula: C₅H₈N₂
• Molecular Weight: 96.13042
• Mol File: 13808-71-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS PAO-1148(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS PAO-1148(13808-71-4)
• EPA Substance Registry System: AKOS PAO-1148(13808-71-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 13808-71-4(Hazardous Substances Data)

Usage

General Description

AKOS PAO-1148 is a chemical compound with the molecular formula C22H26N2O2. It is a quinoline derivative and has been reported to have various biological activities, including anticancer and antiviral properties. It is also known to have some level of cytotoxic effects on certain cell lines. AKOS PAO-1148 is used in pharmaceutical research and drug development as a potential therapeutic agent for various diseases. Additionally, it has been studied for its potential use as an antimalarial agent. Overall, AKOS PAO-1148 is a versatile compound with potential applications in various medical fields.

Upstream product

• 23486-70-6 3-ethynyl-1⁽²⁾H-pyrazole 
• 6261-22-9 pent-2-yn-1-ol 
• 6137-82-2 (E)-1-(N,N-dimethylamino)-1-penten-3-one 
• 55136-52-2 pent-2-yn-1-al 
• 107-00-6 but-1-yne 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 18387-58-1 1-(trimethylsilyl)-1-pentyne-3-one 
• 66376-20-3 3-ethyl-5-trimethylsilanyloxy-4,5-dihydro-isoxazole 
• 58953-12-1 (E)-1-chloropent-1-en-3-one 

Downstream Products

• 530091-61-3 methyl 2-chloro-4-(3-ethyl-1H-pyrazol-1-yl)benzoate 
• 15802-79-6 4-bromo-3-ethyl-1H-pyrazole 
• 701212-55-7 (R)-1-benzoyl-2-methyl-4-[(4-methoxy-7-(3-ethyl-pyrazol-1-yl)-6-azaindol-3-yl)-oxoacetyl]piperazine 

Relevant articles and documents

-

-

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists

The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: wherein, generally, Q is R1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C1-4alkyl or halogen, such as methyl, fluorine or bromine; R2 is hydrogen or C1-4alkyl such as methyl; R3 is phenyl; R4 is hydrogen; R5 is hydrogen or C1-6alkylcarbonyl such as methylcarbonyl; X is —SO2— or —C(O)N(R2)SO2— where R2 is preferably hydrogen; Y is a bond, CH2 or Z1 where Z1 is —N(Rf)— in which Rf is C1-6alkylcarbonyl such as ethylcarbonyl; and R6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C1-6alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.